Insider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 10,746 Shares of Stock

Aileron Therapeutics, Inc. (NASDAQ:ALRN) major shareholder Of Texas/Texas Am I. University sold 10,746 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $4.95, for a total transaction of $53,192.70. Following the transaction, the insider now directly owns 1,799,711 shares of the company’s stock, valued at $8,908,569.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Aileron Therapeutics Trading Down 8.6 %

ALRN opened at $4.16 on Thursday. The firm’s 50 day simple moving average is $5.43 and its two-hundred day simple moving average is $3.82. The company has a market capitalization of $70.60 million, a PE ratio of -1.23 and a beta of 2.22. Aileron Therapeutics, Inc. has a 1-year low of $1.01 and a 1-year high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last released its earnings results on Monday, April 15th. The company reported ($1.54) earnings per share for the quarter. Equities analysts forecast that Aileron Therapeutics, Inc. will post -0.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH upped their price objective on Aileron Therapeutics from $9.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, April 18th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aileron Therapeutics stock. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 15,773 shares of the company’s stock, valued at approximately $48,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.32% of Aileron Therapeutics at the end of the most recent reporting period. 90.89% of the stock is currently owned by institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.